RxDoctor Payments Data

Brittney Dirnberger

Family · Sikeston, MONPI 1013580968

Payments from drug & device makers

$2,244in general payments, 2019–2025

Across 107 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$415
  • Johnson & Johnson$310
  • Madrigal Pharmaceuticals$290
  • Teva Pharmaceuticals USA, Inc.$142
  • Enterra Medical, Inc.$126
  • SK Life Science, Inc.$92
  • plus $870 from 22 others

What the payments were for

  • Travel & lodging$984%
  • Food & beverage$2,02390%
  • Education$1246%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,244 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$12,829
Medicare patients
123
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase50$139,623
LinzessLinaclotide99$72,075
MotegrityPrucalopride Succinate12$9,086
MovantikNaloxegol Oxalate12$4,789
Dexlansoprazole DrDexlansoprazole23$4,570
Pantoprazole Sodium320$3,146
Esomeprazole Magnesium17$2,937
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates46$2,926
Lubiprostone33$2,871
Omeprazole176$2,821
Rabeprazole Sodium59$1,496
Colestipol Hcl31$1,280
Famotidine102$511
Sucralfate37$440
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$52$211,698149 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$46$9,08612 claims
Redhill Biopharma Inc.Movantik$29$4,78912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →